Education
- PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
- MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
- BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
Research Summary
We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.Awards
- Forbeck Fellow, 2015
Recent Publications
- Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Bedognetti, D, Ceccarelli, M, Galluzzi, L, Lu, R, Palucka, K, Samayoa, J, Spranger, S, Warren, S, Wong, KK, Ziv, E et al.. 2019. J Immunother Cancer 7, 167.
doi: 10.1186/s40425-019-0640-yPMID:31272507 - Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Momin, N, Mehta, NK, Bennett, NR, Ma, L, Palmeri, JR, Chinn, MM, Lutz, EA, Kang, B, Irvine, DJ, Spranger, S et al.. 2019. Sci Transl Med 11, .
doi: 10.1126/scitranslmed.aaw2614PMID:31243150 - Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Bedognetti, D, Ceccarelli, M, Galluzzi, L, Lu, R, Palucka, K, Samayoa, J, Spranger, S, Warren, S, Wong, KK, Ziv, E et al.. 2019. J Immunother Cancer 7, 131.
doi: 10.1186/s40425-019-0602-4PMID:31113486 - WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Luke, JJ, Bao, R, Sweis, RF, Spranger, S, Gajewski, TF. 2019. Clin. Cancer Res. 25, 3074-3083.
doi: 10.1158/1078-0432.CCR-18-1942PMID:30635339 - WNT Signaling in Cancer Immunosurveillance. Galluzzi, L, Spranger, S, Fuchs, E, López-Soto, A. 2019. Trends Cell Biol. 29, 44-65.
doi: 10.1016/j.tcb.2018.08.005PMID:30220580 - A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion. Horton, B, Spranger, S. 2018. Immunity 49, 11-13.
doi: 10.1016/j.immuni.2018.07.001PMID:30021140 - A team effort: natural killer cells on the first leg of the tumor immunity relay race. Fessenden, TB, Duong, E, Spranger, S. 2018. J Immunother Cancer 6, 67.
doi: 10.1186/s40425-018-0380-4PMID:29986768 - Impact of oncogenic pathways on evasion of antitumour immune responses. Spranger, S, Gajewski, TF. 2018. Nat. Rev. Cancer 18, 139-147.
doi: 10.1038/nrc.2017.117PMID:29326431 - Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. Gajewski, TF, Corrales, L, Williams, J, Horton, B, Sivan, A, Spranger, S. 2017. Adv. Exp. Med. Biol. 1036, 19-31.
doi: 10.1007/978-3-319-67577-0_2PMID:29275462 - Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Horton, BL, Williams, JB, Cabanov, A, Spranger, S, Gajewski, TF. 2018. Cancer Immunol Res 6, 14-24.
doi: 10.1158/2326-6066.CIR-17-0249PMID:29097422